Xaluritamig for prostate cancer after lutetium treatment
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug called xaluritamig for men with advanced prostate cancer that didn't respond well to the standard lutetium treatment. The goal is to see if this drug can help shrink the cancer or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced prostate cancer that has spread and doesn't respond to hormone therapy.
- You have already had two rounds of a treatment called lutetium (Pluvicto) within the last 4 months, but your PSA level didn't drop enough.
- You have either a tumor that can be seen on scans or a PSA level of at least 2.
- You are generally healthy enough for daily activities (ECOG score 0-2) and expected to live more than 6 months.
- You agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called xaluritamig given before surgery for men with localized prostate cancer that is intermediate or high risk. The goal is to see if it can help shrink the cancer before the prostate is removed.
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This trial tests a radioactive drug (lutetium) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
This trial tests a new drug called xaluritamig for men with metastatic prostate cancer that is resistant to hormone therapy. It is designed for those who have already tried certain hormone pills and one type of chemotherapy, and aims to see if the drug can shrink tumors or slow cancer growth.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.